
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is positioned favorably in the biotechnology sector due to its Enhanced Delivery Oligonucleotide platform, which demonstrates a significant capacity for improving the delivery and efficacy of oligonucleotide therapeutics across various tissues. Notably, the company has reported a 53.7% splicing correction in preclinical studies for its product PGN-EDO53, which surpasses competitors' results and suggests a promising future for muscle performance improvements with repeat dosing in upcoming trials. With shares currently trading at approximately $4, the potential for substantial upside exists contingent on favorable outcomes from multi-dose data, aligning with the broader market sentiment reflected in similar companies’ valuations.
Bears say
PepGen Inc. is facing a negative outlook due to a recent adjustment in its target price, which reflects a $1 decrease to $8 per share, indicative of broader concerns regarding the company's market performance despite promising data from its drug pipeline. The company’s market valuation appears increasingly anomalous, particularly when compared to competitors like Dyne, which have demonstrated regulatory momentum and a more favorable position. Additionally, potential failures in commercial execution or challenges in accessing capital markets could lead to delays or termination of its development campaigns, further jeopardizing its financial stability and growth prospects.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares